Interlaboratory variation in factor VIII:C inhibitor assay results is sufficient to influence patient management: data from the UK national quality external assessment scheme for blood coagulation.
Coagulation Inhibitor Potential: a study of assay variables.
Andresen MS, Abildgaard U.
Thromb Res. 2005;115(6):519-26. doi: 10.1016/j.thromres.2004.11.018. Epub 2004 Dec 16.
Pearls and pitfalls in factor inhibitor assays.
Adcock DM, Favaloro EJ.
Int J Lab Hematol. 2015 May;37 Suppl 1:52-60. doi: 10.1111/ijlh.12352.
Advances in monitoring anticoagulant therapy.
Božič Mijovski M.
Adv Clin Chem. 2019;90:197-213. doi: 10.1016/bs.acc.2019.01.005. Epub 2019 Feb 21.
Inhibitor economics.
Teitel J.
Semin Hematol. 2006 Apr;43(2 Suppl 4):S14-7. doi: 10.1053/j.seminhematol.2006.03.004.
Nature of von Willebrand factor: a new assay and a specific inhibitor.
Sarji KE, Stratton RD, Wagner RH, Brinkhous KM.
Proc Natl Acad Sci U S A. 1974 Aug;71(8):2937-41. doi: 10.1073/pnas.71.8.2937.
High Titer of Acquired Factor V Inhibitor Presenting with a Pseudo-deficiency of Multiple Coagulation Factors.
Nakata K, Ueda S, Matsunaga H, Mima F, Ueda H, Yoshioka A, Kaneko S, Maruo K, Morris S, Yonemoto S, Hayashi D, Fujii N, Narahara H, Inui Y, Kawata S.
Intern Med. 2018 Feb 1;57(3):393-397. doi: 10.2169/internalmedicine.9150-17. Epub 2017 Nov 1.
Acquired coagulation factor inhibitors.
Saraya AK, Pati HP.
J Assoc Physicians India. 1992 Jan;40(1):11-2.
Coagulation inhibitors.
Corrigan JJ Jr.
Am J Pediatr Hematol Oncol. 1980 Fall;2(3):281-8.
Coagulation factors and their inhibitors.
Stubbs MT, Bode W.
Curr Opin Struct Biol. 1994 Dec;4(6):823-32. doi: 10.1016/0959-440x(94)90263-1.
One-stage vs. chromogenic assays in haemophilia A.
Potgieter JJ, Damgaard M, Hillarp A.
Eur J Haematol. 2015 Feb;94 Suppl 77:38-44. doi: 10.1111/ejh.12500.
